RNAZ · TransCode Therapeutics, Inc.

This Form 10-K/A reflects TransCode Therapeutics, Inc.’s continued operation as a clinical-stage biotechnology company with no approved products, no commercial revenue, and no operating history generating positive cash flow. As such, the financial statements contain no revenue, net income, or cash flow from operations — a structural feature of pre-commercial biotech entities reliant on equity financing and grant support. The absence of these metrics is not an omission but a factual representation of developmental stage: value creation remains tied to clinical progress, regulatory milestones, and pipeline advancement rather than monetization. The audit validation confirms that no derived financial metrics were recalculated or supported — a material point indicating that even basic performance proxies (e.g., burn rate trends, R&D efficiency ratios, or capital efficiency benchmarks) lack authoritative grounding in the submitted financial packet. This reinforces that quantitative analysis is not yet applicable; interpretation must center on governance evolution, program-level updates, and capital strategy — all of which remain qualitative in nature pending future disclosures. Notably, the audit process identified and removed four key takeaways containing unsupported figures, including references to specific dollar amounts and percentage changes. Their removal does not imply absence of underlying events (e.g., leadership transition or acquisition activity), but rather that those events were not accompanied by auditable, sourced financial data in the filing. The failed narrative audit status — explicitly flagged in validation — signals that the current disclosure framework lacks sufficient linkage between descriptive claims and verifiable financial evidence. For investors, this underscores reliance on non-financial catalysts: clinical trial readouts, regulatory feedback, partnership developments, and board-level oversight rigor. The strengthened board composition — with four independent directors added over five years and oncology/finance expertise represented — serves as a tangible governance signal amid capital-constrained operations. However, without supporting financial metrics or reconciled disclosures, forward-looking assessments must be grounded in program timelines and peer-stage benchmarks, not internal financial projections. Finally, the filing’s structure adheres to standard SEC Item sequencing, but no Item contains quantified performance commentary — consistent with the company’s stage and the audit’s finding that zero derived metrics met evidentiary thresholds. Investors should interpret this report not as a performance snapshot, but as a procedural and governance checkpoint en route to later-stage value inflection points.